• Treatment of patients with NOX66 commences
• Clinical-stage status achieved within 7 months of IPO
• Clinical strategy designed to deliver proof-of-concept data by end of 2017
• ‘Smarter’ form of idronoxil identified
• Non-oncology pipeline commences.
Noxopharm Ltd is pleased to release its Appendix 4C for the quarter ended 31st March, 2017.
For further information please download PDF attached:
Download this document
